Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText. Kick-your-searchterm to multiple Engines kick-your-query now !>

A dictionary by aggregated review articles of nephrology, medicine and the life sciences Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

10.1111/ajt.16141 http://scihub22266oqcxt.onion/10.1111/ajt.16141 32529737!7307110!32529737     free     free     free Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534 Deprecated: Implicit conversion from float 229.6 to int loses precision in C:\Inetpub\vhosts\kidney.de\httpdocs\pget.php on line 534       Am+J+Transplant 2020 ; 20 (11): 3173-3181 Nephropedia Template TP {{tp|p=32529737|t=2020. Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2?|pdf=|usr=}}{{32529737}} gab.com Text Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2 JO: Am J Transplant http://www.kidney.de/pget.php?&tw=1&pmid=32529737 #FOAvip Minimization of immunosuppression and administration of antiretrovirals have been recommended for kidney transplant recipients (KTRs) with coronavirus disease 2019 (COVID-19). However, outcomes remain poor. Given the likely benefit of cyclosporine because of its antiviral and immunomodulatory effect, we have been using it as a strategy in KTRs diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied 29 kidney transplant recipients (KTRs) who were admitted to our institution with COVID-19 between March 15and April, 24, 2020. Mycophenolate and/or mammalian target of rapamycin inhibitors (mTORi) were discontinued in all patients. Two therapeutic strategies were compared: Group 1, minimization of calcineurin inhibitors (N = 6); and Group 2, cyclosporine-based therapy (N = 23), with 15 patients switched from tacrolimus. Hydroxychloroquine was considered in both strategies but antivirals in none. Six patients died after respiratory distress (20.6%). Five required mechanical ventilation (17.2%), and 3 could be weaned. Nineteen patients had an uneventful recovery (65.5%). In group 1, 3 of 6 patients died (50%) and 1 of 6 required invasive mechanical ventilation (16.7%). In group 2, 3 of 23 patients died (12.5%). Renal function did not deteriorate and signs of rejection were not observed in any patient on the second treatment regime. In conclusion, immunosuppressant treatment based on cyclosporine could be safe and effective for KTRs diagnosed with COVID-19. Twit Text FOAVip Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2 ????Am J Transplant http://www.kidney.de/pget.php?&tw=1&pmid=32529737 #FOAvip Twit Text # Free Paper on # # # # # LINK http://www.kidney.de/pget.php?&tw=1&pmid=32529737 #FOAvip English Wikipedia <ref>{{Cite pmid|32529737}}</ref> Should cyclosporine be useful in renal transplant recipients affected by SARS-CoV-2? #MMPMID32529737 Rodriguez-Cubillo B; de la Higuera MAM; Lucena R; Franci EV; Hurtado M; Romero NC; Moreno AR; Valencia D; Velo M; Fornie IS; Sanchez-Fructuoso AI Am J Transplant 2020[Nov]; 20 (11): 3173-3181 PMID32529737show ga Minimization of immunosuppression and administration of antiretrovirals have been recommended for kidney transplant recipients (KTRs) with coronavirus disease 2019 (COVID-19). However, outcomes remain poor. Given the likely benefit of cyclosporine because of its antiviral and immunomodulatory effect, we have been using it as a strategy in KTRs diagnosed with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We studied 29 kidney transplant recipients (KTRs) who were admitted to our institution with COVID-19 between March 15and April, 24, 2020. Mycophenolate and/or mammalian target of rapamycin inhibitors (mTORi) were discontinued in all patients. Two therapeutic strategies were compared: Group 1, minimization of calcineurin inhibitors (N = 6); and Group 2, cyclosporine-based therapy (N = 23), with 15 patients switched from tacrolimus. Hydroxychloroquine was considered in both strategies but antivirals in none. Six patients died after respiratory distress (20.6%). Five required mechanical ventilation (17.2%), and 3 could be weaned. Nineteen patients had an uneventful recovery (65.5%). In group 1, 3 of 6 patients died (50%) and 1 of 6 required invasive mechanical ventilation (16.7%). In group 2, 3 of 23 patients died (12.5%). Renal function did not deteriorate and signs of rejection were not observed in any patient on the second treatment regime. In conclusion, immunosuppressant treatment based on cyclosporine could be safe and effective for KTRs diagnosed with COVID-19. |*Kidney Transplantation[MESH] |*SARS-CoV-2[MESH] |Aged[MESH] |Aged, 80 and over[MESH] |COVID-19/*epidemiology[MESH] |Comorbidity[MESH] |Cyclosporine/*therapeutic use[MESH] |Female[MESH] |Graft Rejection/*prevention & control[MESH] |Humans[MESH] |Immunosuppression Therapy/*methods[MESH] |Immunosuppressive Agents/therapeutic use[MESH] |Incidence[MESH] |Male[MESH] |Middle Aged[MESH] |Pandemics[MESH] |Renal Insufficiency/epidemiology/*surgery[MESH] |Retrospective Studies[MESH] |Spain/epidemiology[MESH]Should cyclosporine be useful in renal transplant recipients affected (epmc).pdf DeepDyve Pubget Overpricing